StockData
First Tracks Biotherapeutics, Inc. logo

First Tracks Biotherapeutics, Inc. (TRAX) stock

TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$48.70−1.83 (-3.62%)

Close on Nov 12, 2026Market cap $1.74BP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$1.74B
P/E ratio
–
Price to sales
–
Price to book
11.52
Dividend yield
–
Free cash flow yield
–

Fundamentals

Book value per share
$4.22
Diluted shares
36M

Trading

Previous close
$50.53
Open
$49.08
Day's range
$46.97 – $50.15
Volume
311,346
Average volume (20 days)
718,417
Index membership
Russell 2000 (since Jun 2026), Russell 3000 (since May 2026)
RSI (14 days)
60.6
Volatility (1 year)
123.1%
Relative volume
0.36×

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

PeriodTRAXS&P 500DifferenceTRAX per yearS&P 500 per year
1 month+43.0%-2.7%+45.7 pts
3 months+5.6%-1.7%+7.3 pts

Two years at a glance

Fiscal years 2024 to 2025, USD

Reported period

Press releases

Releases First Tracks Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and
    Results
  2. First Tracks Biotherapeutics Announces $200 Million Private Placement
    Update
  3. 8-K exhibit EX-99.1
    Update
  4. First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in
    Update
  5. First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
    Results
  6. First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
    Results
All press releases and earnings

First Tracks Biotherapeutics stock: common questions

What is First Tracks Biotherapeutics's stock price?

TRAX closed at $48.70 on Nov 12, 2026, down 3.62% on the day.

What is First Tracks Biotherapeutics's market cap?

First Tracks Biotherapeutics was worth $1.74B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.

Does First Tracks Biotherapeutics pay a dividend?

No. First Tracks Biotherapeutics has not paid a cash dividend over the last twelve months.

How many TRAX shares are sold short?

5M shares were sold short at the latest FINRA report, 14.42% of the float, or 6.5 days of average trading volume.

Who are First Tracks Biotherapeutics's competitors?

Companies most similar to First Tracks Biotherapeutics by business, industry and size include LLY, JNJ, ABBV, MRK, AZN.

See a number that looks wrong?